Tenaya Therapeutic

Tenaya Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics for cardiovascular diseases. It operates through its product platforms: gene therapy, cellular regeneration, and precision medicine. The company was founded by Deepak Srivastava, Benoit G. Bruneau, Bruce R. Conklin, Sheng Ding, Saptarsi Haldar, and Eric Olson in August 2016 and is headquartered in South San Francisco, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tenaya Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics for cardiovascular diseases. It operates through its product platforms: gene therapy, cellular regeneration, and precision medicine. The company was founded by Deepak Srivastava, Benoit G. Bruneau, Bruce R. Conklin, Sheng Ding, Saptarsi Haldar, and Eric Olson in 2016 and is headquartered in South San Francisco, CA.

The consensus price target hints at a 367.7% upside potential for Tenaya Therapeutics, Inc. (TNYA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Does Tenaya Therapeutics, Inc. (TNYA) Have the Potential to Rally 368% as Wall Street Analysts Expect?

Received State Licensing to Enable cGMP Manufacturing of Drug Product

Tenaya Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

Tenaya's Precision Medicine Platform Used to Identify HDAC6 Target Using Phenotypic Screening and Machine Learning Algorithms

Tenaya Therapeutics Publishes Preclinical Data in Science Translational Medicine Detailing Discovery of HDAC6 Inhibitor for Treatment of Heart Failure

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics today announced that it has completed the build-out and operational launch of its Genetic Medicines Manufacturing Center.

Tenaya Therapeutics Launches Operations of New Genetic Medicines Manufacturing Center to Support the Development of Potentially First-In-Class Cardiovascular Therapeutics

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics announced that it will present preclinical data at the European Society of Cardiology (ESC) Heart Failure 2022 conference.

Tenaya Therapeutics to Present Preclinical Data on TN-301 HDAC6 Inhibitor at European Society of Cardiology Heart Failure 2022 Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics today provided business and program updates, and reported financial results for the first quarter ended March 31, 2022.

Tenaya Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics announces its presentations at the ASGCT 25th Annual Meeting, taking place May 16–19, 2022.

Tenaya Therapeutics to Present Preclinical Data on Gene Therapy Programs and Platform Capabilities at the American Society of Gene and Cell Therapy 25th Annual Meeting

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics announced that it will present new preclinical data at the Heart Rhythm Society's upcoming annual Heart Rhythm 2022 meeting.

Tenaya Therapeutics to Present Preclinical Data on TN-401 PKP2 Gene Therapy Program at Heart Rhythm 2022

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics provided business and program updates, and reported financial results for the fourth quarter and year-end 2021.

Tenaya Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Updates

Tenaya Therapeutics (TNYA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for Tenaya Therapeutics (TNYA)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics provided a 2022 business update.

Tenaya Therapeutics Provides 2022 Business Updates

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics today announced changes to its Board of Directors.

Tenaya Therapeutics Announces the Addition of Dr. June Lee to its Board of Directors

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics announced today that Faraz Ali, Chief Executive Officer, will participate in the 33rd Annual Piper Sandler Healthcare Conference.

Tenaya Therapeutics to Participate in Upcoming Piper Sandler 33rd Annual Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics today reported business and program updates and third quarter 2021 financial results.

Tenaya Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics announced today that it will present new preclinical data at the ESGCT 28th Annual Congress.

Tenaya Therapeutics to Present Preclinical Data on Its Gene Therapy Programs at the ESGCT 28th Annual Congress

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $TNYA--Tenaya Therapeutics announced today that Faraz Ali, Chief Executive Officer, will participate in upcoming investor and industry conferences.

Tenaya Therapeutics to Participate in Upcoming Investor and Industry Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $TNYA--Tenaya Therapeutics reported business and program updates and second quarter 2021 financial results.

Tenaya Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $TNYA--Tenaya Therapeutics announced that it will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference.

Tenaya Therapeutics to Present at Morgan Stanley 19th Annual Global Healthcare Conference

Tenaya Therapeutics is developing therapies for rare genetic disorders and more prevalent cardiovascular diseases.

Tenaya Therapeutics: Treating Heart Disease Through 3 Product Platforms

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics, Inc. announced today the closing of its underwritten, upsized initial public offering.

Tenaya Therapeutics Announces Closing of Upsized Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics, Inc. announced today the pricing of its underwritten, upsized initial public offering.

News for Tenaya Therapeutic Stock (TNYA)